| Date | Ref. No. | Patent No. | Title |
| 10/7/2009 | E-328-2001/1 | | Use of CpG Oligodeoxynucleotides to Induce Epithelial Cell Growth |
| 10/7/2009 | E-147-1999/0
E-147-1999/1 | 6,977,245 | Oligodeoxynucleotide and Its Use To Induce an Immune Response |
| 9/21/2009 | E-299-2008/0 | | Improved Immunotherapeutic Compositions for Treatment, Diagnosis and Prevention of HIV |
| 9/3/2009 | E-169-2004/0
E-281-2005/0
E-318-2000/0 | | Rapid Diagnostic Applications of Phage |
| 8/11/2009 | E-010-1994/0 | 5,610,060 | Isolated Helicobacter hepaticus |
| 7/2/2009 | E-152-2009/0 | | qPCR Assay for Detection of JC Virus |
| 6/1/2009 | E-114-2009/0 | | Axenically-Produced Coxiella burnetii and Methods for Producing Axenic Coxiella burnetii |
| 5/4/2009 | E-296-2008/0 | | Anti-Cancer Oligodeoxynucleotides |
| 3/23/2009 | E-304-2008/0 | | M2e Peptide Vaccine Against Influenza Virus |
| 2/17/2009 | E-173-2008/0 | | Compositions and Methods for Vaccine and Virus Production |
| 1/9/2009 | E-182-2008/0 | | Method of Treating Pneumoconiosis with Oligodeoxynucleotides |
| 10/1/2008 | E-204-2007/0 | | Methods of Glycosylation and Bioconjugation |
| 10/1/2008 | E-240-2007/0 | | Development of Antigenic Chimeric St. Louis Encephalitis Virus/Dengue Virus Type Four Recombinant Viruses (SLEV/DEN4) as Vaccine Candidates for the Prevention of Disease Caused by SLEV |
| 10/1/2008 | E-279-2007/0 | | Alpha 1-3 N-Acetylgalactosaminyltransferases with Altered Donor and Acceptor Specificities, Compositions, and Methods of Use |
| 10/1/2008 | E-280-2007/0 | | Beta 1,4-Galactosyltransferases with Altered Donor and Acceptor Specificities, Compositions and Methods of Use |
| 10/1/2008 | E-183-2002/0 | | Method of Treating Infectious and Inflammatory Lung Disease with Suppressive Oligonucleotides |
| 10/1/2008 | E-153-2002/0 | | Method of Treating and Preventing Infections in Immunocompromised Subjects with Immunostimulatory CpG Oligonucleotides |
| 10/1/2008 | E-230-2002/2 | 7,482,133 | Catalytic Domains of [beta](1,4)-galactosyltransferase I Having Altered Donor and Acceptor Specificities, Domains That Promote In Vitro Protein Folding, and Methods for Their Use |
| 9/1/2008 | E-149-2006/2 | | Compositions and Methods for Increasing Recombinant Protein Yields through the Modification of Cellular Properties |
| 9/1/2008 | E-023-2002/0 | | Methods for Preparing Bacillus anthracis Protective Antigen for Use in Vaccines |
| 8/1/2005 | E-075-2001/0 | | Methods and Compositions for Production and Purification of Recombinant Staphylococcal Enterotoxin B (rSEB) |
| 8/1/2005 | E-318-2000/0 | | Method for Determining Sensitivity to a Bacteriophage |
| 6/1/2005 | E-121-2004/0 | | A New Antiviral Pathway that is Responsible for Viral Clearance: Modulation of ADAR1 Activities Enhance Antiviral Therapies and Virus Infection of Tissue Culture Systems |
| 4/1/2005 | E-176-2003/0 | | Antibodies Against the Amino Terminus Region of Circumsporozoite Protein Prevent the Onset of Malaria |
| 12/1/2004 | E-004-2005/0
E-004-2005/4 | | Human Monoclonal Antibodies Against Hendra and Nipah Viruses |
| 6/1/2004 | E-228-2003/1
E-228-2003/2 | | Soluble SARS Coronavirus Spike Protein (S Protein) |
| 11/1/2003 | E-224-2003/0 | | Inhibition of Retrovirus Gene Expression by PSF |
| 5/1/2003 | E-240-2002/0 | | HTLV-1 Cell Binding and Inhibition |
| 1/1/2001 | E-143-1989/0 | 5,459,056 | Human T Cell Line Chronically Infected With HIV |
| 9/1/1999 | E-107-1996/0 | 6,316,190 | Oligonucleotides Which Specifically Bind Retroviral Nucleocapsid Proteins |
| 4/1/1998 | E-061-1997/0 | | Phage Display Of Intact Domains At High Copy Number |
| 11/1/1996 | E-017-1996/1 | 6,197,578 | Cells Expressing Both Human CD4 And A Human Fusion Accessory Factor Associated With HIV Infection |